568 Phase 2 trial of induction and concomitant CTLA4 (ipilimumab) and PD-1 (nivolumab) immune checkpoint blockade and intensity modulated radiation therapy (IMRT) in HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPSCC)

Abstract

BackgroundPD-1 immune checkpoint blockade (ICB) improves survival versus chemotherapy in PD-L1 CPS≥1 recurrent or metastatic head and neck cancer. We evaluated the safety and efficacy of induction and concurrent CTLA4...